Literature DB >> 8780385

Scatter factor binds to thrombospondin and other extracellular matrix components.

K Lamszus1, A Joseph, L Jin, Y Yao, S Chowdhury, A Fuchs, P J Polverini, I D Goldberg, E M Rosen.   

Abstract

Scatter factor (SF) is an angiogenic growth factor that stimulates motility and invasion of carcinoma cells. SF is present in the extracellular matrix (ECM) of breast cancers, where it might act to promote tumor cell invasion and angiogenesis. To investigate how SF is incorporated into the ECM, we studied the binding of SF to various ECM components using a solid-phase binding assay based on the SF enzyme-linked immunosorbent assay. We found that SF binds to a variety of ECM molecules, with different binding capacities. The highest SF binding capacities were observed for thrombospondin-1 (TSP-1), fibronectin (Fn), and heparan sulfate proteoglycan, although SF did not bind to albumin. Mature two-chain SF and precursor single-chain SF bound approximately equally well to TSP-1 and Fn. Moreover, two SF alpha-chain peptides (NK1 and NK2) both bound to TSP-1 and Fn, suggesting that the whole SF molecule is not required for binding. Based on binding competition assays, TSP-1 exhibited higher affinity for SF than did nine other ECM molecules, including Fn and heparan sulfate proteoglycan. Although heparin in solution potently inhibited the binding of SF to TSP-1-coated surfaces, even very high concentrations of heparin could not elute SF already bound to TSP-1. SF binding was modulated by binding interactions among ECM molecules (TSP-1-Fn, TSP-1-collagen I, and Fn-collagen I), suggesting that the matrix capacity to bind SF depends upon its exact composition. SF bound in a dose-dependent fashion to ECMs secreted by three human breast carcinoma cell lines. Binding of SF to matrices from all three cell lines was significantly inhibited by preincubation of the matrices with antibodies against TSP-1, whereas antibodies against several other ECM components were less effective or ineffective in inhibiting SF binding. In addition, TSP-1 markedly inhibited chemotaxis of microvascular endothelial cells toward SF and SF-induced angiogenesis in the rat cornea neovascularization assay. Our findings suggest that 1) SF interacts with a variety of ECM components, 2) high affinity SF-TSP-1 interactions may mediate the binding of SF to the breast cancer matrix, and 3) the SF-TSP-1 interaction may contribute to modulation of angiogenesis. Possible implications of these findings for tumor angiogenesis are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780385      PMCID: PMC1865139     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  Identification of a competitive HGF antagonist encoded by an alternative transcript.

Authors:  A M Chan; J S Rubin; D P Bottaro; D W Hirschfield; M Chedid; S A Aaronson
Journal:  Science       Date:  1991-11-29       Impact factor: 47.728

2.  Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast.

Authors:  P Clezardin; L Frappart; M Clerget; C Pechoux; P D Delmas
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

3.  Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study.

Authors:  S Y Wong; A T Purdie; P Han
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

4.  Heparin-binding peptides from the type I repeats of thrombospondin. Structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis.

Authors:  N H Guo; H C Krutzsch; E Nègre; V S Zabrenetzky; D D Roberts
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

5.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.

Authors:  S Rong; M Bodescot; D Blair; J Dunn; T Nakamura; K Mizuno; M Park; A Chan; S Aaronson; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

6.  Scatter factor is a glycoprotein but glycosylation is not required for its activity.

Authors:  R Hofmann; A Joseph; M M Bhargava; E M Rosen; I Goldberg
Journal:  Biochim Biophys Acta       Date:  1992-04-17

7.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.

Authors:  N Weidner; J Folkman; F Pozza; P Bevilacqua; E N Allred; D H Moore; S Meli; G Gasparini
Journal:  J Natl Cancer Inst       Date:  1992-12-16       Impact factor: 13.506

Review 8.  The role of angiogenesis in tumor growth.

Authors:  J Folkman
Journal:  Semin Cancer Biol       Date:  1992-04       Impact factor: 15.707

9.  The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors.

Authors:  E W Raines; T F Lane; M L Iruela-Arispe; R Ross; E H Sage
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

10.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  13 in total

1.  Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage.

Authors:  D Pfander; T Cramer; D Deuerling; G Weseloh; B Swoboda
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

2.  Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.

Authors:  Shaoliang Li; Chisei Shimono; Naoko Norioka; Itsuko Nakano; Tetsuo Okubo; Yoshiko Yagi; Maria Hayashi; Yuya Sato; Hitomi Fujisaki; Shunji Hattori; Nobuo Sugiura; Koji Kimata; Kiyotoshi Sekiguchi
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

3.  NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo.

Authors:  J L Jakubczak; W J LaRochelle; G Merlino
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

4.  Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis.

Authors:  Randall E Ryan; Bryan Martin; Liliana Mellor; Reed B Jacob; Ken Tawara; Owen M McDougal; Julia Thom Oxford; Cheryl L Jorcyk
Journal:  Cytokine       Date:  2015-01-23       Impact factor: 3.861

Review 5.  Contribution of Human Thrombospondin-1 to the Pathogenesis of Gram-Positive Bacteria.

Authors:  Ulrike Binsker; Thomas P Kohler; Sven Hammerschmidt
Journal:  J Innate Immun       Date:  2019-02-27       Impact factor: 7.349

6.  High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques.

Authors:  Xue Qin; Qiaopei Chen; Chun Sun; Cun Wang; Qiliu Peng; Li Xie; Yinkun Liu; Shan Li
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

7.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Authors:  Yu-Wen Zhang; Yanli Su; Olga V Volpert; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

8.  The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism.

Authors:  Noboru Hattori; Shinya Mizuno; Yuka Yoshida; Kazuo Chin; Michiaki Mishima; Thomas H Sisson; Richard H Simon; Toshikazu Nakamura; Masayuki Miyake
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

Review 9.  Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors.

Authors:  Giulia Taraboletti; Marco Rusnati; Laura Ragona; Giorgio Colombo
Journal:  Oncotarget       Date:  2010-11

10.  Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.

Authors:  Amanda Tate; Shuji Isotani; Michael J Bradley; Robert A Sikes; Rodney Davis; Leland W K Chung; Magnus Edlund
Journal:  BMC Cancer       Date:  2006-07-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.